Advertisement

Tumor Biology

, Volume 36, Issue 12, pp 9385–9393 | Cite as

Quercetin 3-O-glucoside suppresses epidermal growth factor–induced migration by inhibiting EGFR signaling in pancreatic cancer cells

  • Jungwhoi Lee
  • Song-I Han
  • Jeong-Hun Yun
  • Jae Hoon Kim
Research Article

Abstract

Pancreatic cancer is one of the most dangerous cancers and is associated with a grave prognosis. Despite increased knowledge of the complex signaling networks responsible for progression of pancreatic cancer, many challenging therapies have fallen short of expectations. In this study, we examined the anti-migratory effect of quercetin 3-O-glucoside in epidermal growth factor–induced cell migration by inhibiting EGF receptor (EGFR) signaling in several human pancreatic cancer cell lines. Treatment with quercetin, quercetin 3-O-glucoside, and quercetin 7-O-glucoside differentially suppressed epidermal growth factor–induced migration activity of human pancreatic cancer cells. In particular, quercetin 3-O-glucoside strongly inhibited the infiltration activity of pancreatic cancer cells in a dose-dependent manner. Furthermore, quercetin 3-O-glucoside exerted the anti-migratory effect even at a relatively low dose compared with other forms of quercetin. The anti-tumor effects of quercetin 3-O-glucoside were mediated by selectively inhibiting the EGFR-mediated FAK, AKT, MEK1/2, and ERK1/2 signaling pathway. Combinatorial treatment with quercetin 3-O-glucoside plus gemcitabine showed the synergistic anti-migratory effect on epidermal growth factor–induced cell migration in human pancreatic cancer cell lines. These results suggest that quercetin 3-O-glucoside has potential for anti-metastatic therapy in human pancreatic cancer.

Keywords

Quercetin Quercetin-3-O-glucoside EGF EGFR FAK ERK/1/2 Migration Pancreatic cancers 

Notes

Acknowledgments

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2009-0094059).

Conflicts of interest

None

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64:9–29.Google Scholar
  2. 2.
    Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163–72.CrossRefPubMedGoogle Scholar
  3. 3.
    Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897–909.CrossRefPubMedGoogle Scholar
  4. 4.
    Cano CE, Motoo Y, Iovanna JL. Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. Sci World J. 2010;10:1947–57.CrossRefGoogle Scholar
  5. 5.
    Inoue S, Tezel E, Nakao A. Molecular diagnosis of pancreatic cancer. Hepato-Gastroenterology. 2001;48:933–8.PubMedGoogle Scholar
  6. 6.
    Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol : Int J Published British Ind Biol Res Assoc. 1995;33:1061–80.CrossRefGoogle Scholar
  7. 7.
    Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3:768–80.CrossRefPubMedGoogle Scholar
  8. 8.
    Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol. 2012;83:6–15.CrossRefPubMedGoogle Scholar
  9. 9.
    Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr. 2012;31:206–38.CrossRefPubMedGoogle Scholar
  10. 10.
    Yang JH, Hsia TC, Kuo HM, Chao PD, Chou CC, Wei YH, et al. Inhibition of lung cancer cell growth by quercetin glucuronides via g2/m arrest and induction of apoptosis. Drug Metab Disposition: Biol Fate Chem. 2006;34:296–304.CrossRefGoogle Scholar
  11. 11.
    Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, et al. Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med: eCAM. 2011;2011:591356.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008;269:315–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Razavi SM, Zahri S, Zarrini G, Nazemiyeh H, Mohammadi S. Biological activity of quercetin-3-o-glucoside, a known plant flavonoid. Bioorg Khim. 2009;35:414–6.PubMedGoogle Scholar
  14. 14.
    Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Oliveira-Cunha M, Newman WG, Siriwardena AK. Epidermal growth factor receptor in pancreatic cancer. Cancers. 2011;3:1513–26.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lee J, Lee J, Yu H, Choi K, Choi C. Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer Lett. 2011;309:145–50.CrossRefPubMedGoogle Scholar
  17. 17.
    Lee J, Ku T, Yu H, Chong K, Ryu SW, Choi K, et al. Blockade of vegf-a suppresses tumor growth via inhibition of autocrine signaling through fak and akt. Cancer Lett. 2012;318:221–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Investig. 1992;90:1352–60.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Pryczynicz A, Guzinska-Ustymowicz K, Kemona A, Czyzewska J. Expression of egf and egfr strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res. 2008;28:1399–404.PubMedGoogle Scholar
  20. 20.
    Angst E, Park JL, Moro A, Lu QY, Lu X, Li G, et al. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas. 2013;42:223–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, et al. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 2010;37:551–61.PubMedGoogle Scholar
  22. 22.
    Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, et al. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res. 2002;22:1615–27.PubMedGoogle Scholar
  23. 23.
    Morand C, Manach C, Crespy V, Remesy C. Quercetin 3-o-beta-glucoside is better absorbed than other quercetin forms and is not present in rat plasma. Free Radic Res. 2000;33:667–76.CrossRefPubMedGoogle Scholar
  24. 24.
    Du XY, Huang J, Xu LQ, Tang DF, Wu L, Zhang LX, et al. The proto-oncogene c-src is involved in primordial follicle activation through the pi3k, pkc and mapk signaling pathways. Reprod Biol Endocrinol : RB&E. 2012;10:58.CrossRefGoogle Scholar
  25. 25.
    Roby KF, Son DS, Taylor CC, Montgomery-Rice V, Kirchoff J, Tang S, et al. Alterations in reproductive function in src tyrosine kinase knockout mice. Endocrine. 2005;26:169–76.CrossRefPubMedGoogle Scholar
  26. 26.
    Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of canada clinical trials group. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25:1960–6.CrossRefGoogle Scholar
  27. 27.
    Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMedGoogle Scholar
  28. 28.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRefGoogle Scholar
  29. 29.
    Aranda E, Manzano JL, Rivera F, Galan M, Valladares-Ayerbes M, Pericay C, et al. Phase ii open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (pantar study). Ann Oncol : Off J Europ Soc Med Oncol/ESMO. 2012;23:1919–25.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Jungwhoi Lee
    • 1
  • Song-I Han
    • 1
  • Jeong-Hun Yun
    • 1
  • Jae Hoon Kim
    • 1
    • 2
  1. 1.Faculty of Biotechnology, College of Applied Life Science, SARIJeju National UniversityJejuKorea
  2. 2.Subtropical Horticulture Research InstituteJeju National UniversityJejuKorea

Personalised recommendations